Eupraxia Pharmaceuticals Reports Strong EREFS Data for EP-104GI in EoE RESOLVE Trial
EPRX has more than doubled off its 52-week low of $3.667.
Summary
Eupraxia Pharmaceuticals announced positive Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its Phase 1b/2a RESOLVE trial for EP-104GI, demonstrating significant improvements in inflammation and fibrosis.
Key Events · Product Development and Regulatory · EPRX
-
Positive EREFS Data Reported
Eupraxia Pharmaceuticals announced the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its Phase 1b/2a RESOLVE trial for EP-104GI, presented at Digestive Disease Week (DDW).
-
Significant Improvement in EoE Severity
Patients receiving 20 injections of EP-104GI showed a mean 65% (3.6 points) reduction in EREFS from baseline at week 12, demonstrating consistent improvement in both inflammatory and fibrotic sub-scores.
-
Validation for Phase 2b Dose Selection
The data supports the selection of 20 injections for higher esophageal surface coverage, which is the number of injections being studied in the ongoing placebo-controlled Phase 2b portion of the RESOLVE trial.
-
Phase 2b Top-Line Data Expected Q4 2026
The Phase 2b part of the RESOLVE trial is currently recruiting, with top-line data anticipated in the fourth quarter of 2026.
Analysis · EPRX · Life Sciences
The reported EREFS data from the RESOLVE trial provides crucial validation for EP-104GI in treating Eosinophilic Esophagitis (EoE). The dose-dependent improvements, particularly the 65% reduction in EREFS with 20 injections, strongly support the selection of this injection pattern for the ongoing placebo-controlled Phase 2b trial. This de-risks the clinical program and offers a positive signal for the drug's potential efficacy, which is vital for a clinical-stage biotechnology company. Investors will likely view this as a significant step forward, reinforcing confidence in the drug's development ahead of Phase 2b top-line data expected in Q4 2026. This filing provides the specific detailed data that was previously hinted at in the 6-K filings on April 21 and April 22, 2026.
At the time of this filing, EPRX was trading at $7.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $456.4M. The 52-week trading range was $3.67 to $9.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.